In a May 21 update, Ventum Capital Markets analyst Andrew Semple maintained a “Buy” rating and $0.50 target for Vext Science (Vext Science Stock Quote, Chart, News, Analysts, Financials CSE:VEXT), citing stronger-than-expected cash flow and improving liquidity.
Vext reported $3.1-million in operating cash flow for the quarter, well above the forecasted $0.5-million, which helped reduce debt and ease prior concerns about its 2025 liquidity. Semple said the company is now well-positioned to fund growth.
Vext Science operates cannabis production facilities and retail dispensaries in several U.S. states. Its core business includes two vertically integrated cannabis licensees in Arizona and similar operations in Ohio, with joint venture prospects in other states.
Semple said cash flow remains strong and that new Ohio stores are expected to drive growth in 2025 and 2026. Vext Science reported strong Q1 2025 results,…
